注射用乌司他丁联合醋酸奥曲肽注射液治疗重症急性胰腺炎的临床效果  

Clinical effect of ulinastatin for injection combined with octreotide acetate injection in the treatment of severe acute pancreatitis

作　　者：王慧 WANG Hui(Department of Pharmacy,Liangzhou District Integrated Traditional and Western Medicine Hospital,Gansu Province,Wuwei 733000,China)

机构地区：[1]甘肃省武威市凉州区中西医结合医院药剂科,733000

出　　处：《临床合理用药杂志》2024年第21期28-31,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的 观察注射用乌司他丁联合醋酸奥曲肽注射液治疗重症急性胰腺炎(SAP)的临床效果。方法 选取2021年1月—2023年5月凉州区中西医结合医院收治的SAP患者80例,按照随机数字表法分为奥曲肽组(40例)和联合治疗组(40例)。奥曲肽组给予醋酸奥曲肽注射液治疗,联合治疗组在奥曲肽组基础上加用注射用乌司他丁治疗,2组均治疗7 d。比较2组临床疗效,治疗前后血清炎性因子[单核细胞趋化蛋白-1(MCP-1)、白介素-1β(IL-1β)、高迁移率族蛋白B1(HMGB1)]、免疫功能指标[免疫球蛋白(Ig)A、IgM、IgG],不良反应。结果 联合治疗组治疗总有效率高于奥曲肽组(87.50%vs.67.50%,χ^(2)=4.588,P=0.032)。治疗7 d后,2组血清MCP-1、IL-1β、HMGB1水平低于治疗前,且联合治疗组低于奥曲肽组(P均<0.01);2组血清IgA、IgM、IgG水平高于治疗前,且联合治疗组高于奥曲肽组(P均<0.01)。联合治疗组不良反应总发生率与奥曲肽组比较差异无统计学意义(20.00%vs.32.50%,χ^(2)=1.614,P=0.204)。结论 注射用乌司他丁联合醋酸奥曲肽注射液治疗SAP的临床效果显著,可有效抑制炎性因子分泌,调节机体免疫功能,加速缓解临床症状,且安全性较高。Objective To observe the clinical effect of ulinastatin for injection combined with octreotide acetate injection in the treatment of SAP.Methods A total of 80 patients with SAP admitted to Liangzhou District Integrated Traditional and Western Medicine Hospital from January 2021 to May 2023 were selected and divided into the octreotide group(40 cases) and the combination therapy group(40 cases) according to the random number table method.The octreotide group was treated with octreotide acetate injection,and the combination therapy group was treated with ulinastatin for injection on the basis of the octreotide group,and both groups were treated for 7 days.The clinical efficacy,serum inflammatory factors(MCP-1,IL-1β,HMGB1),immune function indicators(IgA,IgM,IgG) before and after treatment,and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the combination therapy group was higher than that in the octreotide group(87.50% vs.67.50%,χ^(2)=4.588,P=0.032).After 7 days of treatment,the serum levels of MCP-1,IL-1β and HMGB1 in the two groups were lower than those before treatment,and the combination therapy group were lower than those in the octreotide group(P<0.01).The levels of IgA,IgM and IgG in the two groups were higher than those before treatment,and the combination therapy group were higher than those in the octreotide group(P<0.01).There was no significant difference in the total incidence of adverse reactions between the combination therapy group and the octreotide group(20.00% vs.32.50%,χ^(2)=1.614,P=0.204).Conclusion The clinical effect of ulinastatin for injection combined with octreotide acetate injection in the treatment of SAP is significant,which can effectively inhibit the secretion of inflammatory factors,regulate the body′s immune function,accelerate the alleviation of clinical symptoms,and has a high safety profile.

关 键 词：重症急性胰腺炎 注射用乌司他丁 醋酸奥曲肽注射液 免疫功能 炎性因子 

分 类 号：R576[医药卫生—消化系统]